Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Social circumstances – page 2

  • 20 clinical trials
  • 9 recruiting
  • 25 conditions
  • 13 countries

Conditions in this area

25 conditions with trials, the busiest first

Disease risk factor5Clinical trial participant3Ex-tobacco user3Menopause3Device dependence2Eye prosthesis user2Smoking cessation therapy2COVID-19 immunisation1Cardiovascular disorder1Critical illness1Diabetes mellitus1Elderly1Eye disorder1Eye inflammation1HIV infection1Haemodialysis1Haemorrhage intracranial1Immunisation1Influenza immunisation1Mechanical ventilation1Menopausal symptoms1Organ donor1Peritoneal dialysis1Rheumatic disorder1+1

Clinical trials in Social circumstances

20 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

20 clinical trials

Menopause

Not yet recruiting

Evaluation of triptorelin, estradiol, and testosterone compared to placebo for changes in bone markers in postmenopausal women

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Region Hovedstaden

Eye inflammation+1

Not yet recruiting

Study on Reducing Eye Prosthesis Discomfort and Discharge Using Retinol Palmitate, Fluorometholone, and Artificial Tears for Patients with Chronic Eye Socket Issues

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Fluorometholone
  • Sponsor:Amsterdam UMC Stichting

Device dependence

Not yet recruiting

Study on Renaparin for Improving Kidney Function in Transplant Patients with End-Stage Renal Disease from Deceased Donors

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Corline Heparin Conjugate
  • Sponsor:Corline Biomedical AB

Device dependence

Not yet recruiting

Study on Renaparin for Improving Kidney Function in Patients with End-Stage Renal Disease Receiving Deceased Donor Transplants

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Corline Heparin Conjugate
  • Sponsor:Corline Biomedical AB

Clinical trial participant

Not recruiting

Study on How Minzasolmin is Absorbed in the Body and its Safety in Healthy Adults

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · Healthy volunteers
  • Substances:Minzasolmin
  • Sponsor:UCB Biopharma

Eye disorder+1

Not recruiting

Study on Reducing Eye Prosthesis Discomfort and Discharge Using Retinol Palmitate, Sodium Hyaluronate, and Fluorometholone for Patients with Chronic Symptoms

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Fluorometholone
  • Sponsor:Amsterdam UMC Stichting

Organ donor

Not recruiting

Study on the Effects of Potassium Canrenoate and Trometamol on Blood Flow in Brain-Dead Organ Donors

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Potassium Canrenoate
  • Sponsor:CHRU De Nancy

Ex-tobacco user

Not recruiting

Study on the Effects of Nicotine Resinate Lozenge on Cravings in Moderate Smokers in Non-Smoking Situations

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Nicotine Resinate
  • Sponsor:Pierre Fabre Medicament

Substances studied in this area

The therapies tested most often in Social circumstances trials.

Colchicine2 clinical trialsCorline Heparin Conjugate2 clinical trialsFluorometholone2 clinical trialsRetinol Palmitate2 clinical trialsRosuvastatin Calcium2 clinical trialsSodium Chloride2 clinical trialsSodium Hyaluronate2 clinical trialsAmlodipine1 clinical trialAtorvastatin1 clinical trial
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.